Review



hedgehog signaling inhibitor vismodegib  (LC Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    LC Laboratories hedgehog signaling inhibitor vismodegib
    Hedgehog Signaling Inhibitor Vismodegib, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hedgehog signaling inhibitor vismodegib/product/LC Laboratories
    Average 90 stars, based on 1 article reviews
    hedgehog signaling inhibitor vismodegib - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    hedgehog signaling inhibitor vismodegib  (Selleck Chemicals)
    94
    Selleck Chemicals hedgehog signaling inhibitor vismodegib
    Figure 2. The effect of <t>vismodegib</t> (A) and PRI-724 (B) on the viability of CAL 27 and FaDu cells after 48 h of incubation, as determined by the resazurin assay. The chemical structure of the compounds is also presented. The results are the mean values from three independent experiments with four technical repeats ± SD.
    Hedgehog Signaling Inhibitor Vismodegib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hedgehog signaling inhibitor vismodegib/product/Selleck Chemicals
    Average 94 stars, based on 1 article reviews
    hedgehog signaling inhibitor vismodegib - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    hedgehog signalling inhibitor vismodegib  (Beyotime)
    90
    Beyotime hedgehog signalling inhibitor vismodegib
    Figure 2. The effect of <t>vismodegib</t> (A) and PRI-724 (B) on the viability of CAL 27 and FaDu cells after 48 h of incubation, as determined by the resazurin assay. The chemical structure of the compounds is also presented. The results are the mean values from three independent experiments with four technical repeats ± SD.
    Hedgehog Signalling Inhibitor Vismodegib, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hedgehog signalling inhibitor vismodegib/product/Beyotime
    Average 90 stars, based on 1 article reviews
    hedgehog signalling inhibitor vismodegib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    hedgehog signaling inhibitor vismodegib  (LC Laboratories)
    90
    LC Laboratories hedgehog signaling inhibitor vismodegib
    Figure 2. The effect of <t>vismodegib</t> (A) and PRI-724 (B) on the viability of CAL 27 and FaDu cells after 48 h of incubation, as determined by the resazurin assay. The chemical structure of the compounds is also presented. The results are the mean values from three independent experiments with four technical repeats ± SD.
    Hedgehog Signaling Inhibitor Vismodegib, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hedgehog signaling inhibitor vismodegib/product/LC Laboratories
    Average 90 stars, based on 1 article reviews
    hedgehog signaling inhibitor vismodegib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. The effect of vismodegib (A) and PRI-724 (B) on the viability of CAL 27 and FaDu cells after 48 h of incubation, as determined by the resazurin assay. The chemical structure of the compounds is also presented. The results are the mean values from three independent experiments with four technical repeats ± SD.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 2. The effect of vismodegib (A) and PRI-724 (B) on the viability of CAL 27 and FaDu cells after 48 h of incubation, as determined by the resazurin assay. The chemical structure of the compounds is also presented. The results are the mean values from three independent experiments with four technical repeats ± SD.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Incubation, Resazurin Assay

    Figure 3. The results of the analysis of the combinatorial effects between PRI-724 and vismodegib, erlotinib, or HS-173 on cell viability by the resazurin assay. CAL 27 and FaDu cells were treated with increasing concentrations (Supplementary Table S1) of the individual compounds and their combinations for 48 h. Control cells were treated with vehicle (DMSO). Mean values from three independent experiments were used in calculations using the CompuSyn software (version 1.0). Dose-effect curves for individual compounds (A) or their combinations (B) were generated. Plots (C) represent the evaluation of the Combination Index (CI), where CI < 1 (the area below the dotted line in plots) denotes a synergistic effect between compounds. Fa—Fraction affected: viability reduction from lack of effect (0) to maximal effect (1; viability = 0%), E—erlotinib, H—HS-173, P—PRI-724, V—vismodegib.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 3. The results of the analysis of the combinatorial effects between PRI-724 and vismodegib, erlotinib, or HS-173 on cell viability by the resazurin assay. CAL 27 and FaDu cells were treated with increasing concentrations (Supplementary Table S1) of the individual compounds and their combinations for 48 h. Control cells were treated with vehicle (DMSO). Mean values from three independent experiments were used in calculations using the CompuSyn software (version 1.0). Dose-effect curves for individual compounds (A) or their combinations (B) were generated. Plots (C) represent the evaluation of the Combination Index (CI), where CI < 1 (the area below the dotted line in plots) denotes a synergistic effect between compounds. Fa—Fraction affected: viability reduction from lack of effect (0) to maximal effect (1; viability = 0%), E—erlotinib, H—HS-173, P—PRI-724, V—vismodegib.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Resazurin Assay, Control, Software, Generated

    Figure 4. The effect of PRI-724, vismodegib, erlotinib, HS-173, and their combinations on the cell cycle distribution in CAL 27 (A) and FaDu (B) cells after 48 h of incubation. The cell cycle distribution (G1/G0, S, and G2/M phases) was measured by flow cytometric analysis of cells after propid- ium iodide staining. DMSO-vehicle-treated cells were used as a negative control, while topotecan (100 nM) was used as a positive control for cell cycle arrest. Exemplary flow cytometry plots are shown on the right side. Mean values ± SD from three independent experiments are shown. The asterisk (*) inside the bars denotes a statistically significant increase in cell population between the analyzed compound used alone or in combination, and the control (ctrl), * p < 0.05, ** p < 0.01; (#) inside the bars denotes a statistically significant decrease in cell population between the analyzed compound used alone or in combination, and the control (ctrl), # p < 0.05, ## p < 0.01.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 4. The effect of PRI-724, vismodegib, erlotinib, HS-173, and their combinations on the cell cycle distribution in CAL 27 (A) and FaDu (B) cells after 48 h of incubation. The cell cycle distribution (G1/G0, S, and G2/M phases) was measured by flow cytometric analysis of cells after propid- ium iodide staining. DMSO-vehicle-treated cells were used as a negative control, while topotecan (100 nM) was used as a positive control for cell cycle arrest. Exemplary flow cytometry plots are shown on the right side. Mean values ± SD from three independent experiments are shown. The asterisk (*) inside the bars denotes a statistically significant increase in cell population between the analyzed compound used alone or in combination, and the control (ctrl), * p < 0.05, ** p < 0.01; (#) inside the bars denotes a statistically significant decrease in cell population between the analyzed compound used alone or in combination, and the control (ctrl), # p < 0.05, ## p < 0.01.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Incubation, Staining, Negative Control, Positive Control, Cytometry, Control

    Figure 5. The effect of PRI-724, vismodegib, erlotinib, HS-173, and their combinations on the induction of apoptosis in CAL 27 (A) and FaDu (B) cells after 48 h of incubation. The apoptotic cells were detected by flow cytometric analysis after Annexin V and 7-Aminoactinomycin D staining. DMSO-vehicle-treated cells were used as a negative control, while topotecan (100 nM) was used as a positive control for apoptosis induction. Exemplary flow cytometry plots are shown on the right side. Mean values ± SD from three independent experiments are shown. The asterisk (*) inside the bars denotes a statistically significant increase in cell population between the analyzed compound used alone or in combination, and the control (ctrl) for early or late apoptotic cells, * p < 0.05, ** p < 0.01; (#) above the bars denotes a statistically significant increase in total apoptotic cells between the analyzed compound used alone or in combination, and the control (ctrl), # p < 0.05, ## p < 0.01.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 5. The effect of PRI-724, vismodegib, erlotinib, HS-173, and their combinations on the induction of apoptosis in CAL 27 (A) and FaDu (B) cells after 48 h of incubation. The apoptotic cells were detected by flow cytometric analysis after Annexin V and 7-Aminoactinomycin D staining. DMSO-vehicle-treated cells were used as a negative control, while topotecan (100 nM) was used as a positive control for apoptosis induction. Exemplary flow cytometry plots are shown on the right side. Mean values ± SD from three independent experiments are shown. The asterisk (*) inside the bars denotes a statistically significant increase in cell population between the analyzed compound used alone or in combination, and the control (ctrl) for early or late apoptotic cells, * p < 0.05, ** p < 0.01; (#) above the bars denotes a statistically significant increase in total apoptotic cells between the analyzed compound used alone or in combination, and the control (ctrl), # p < 0.05, ## p < 0.01.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Incubation, Staining, Negative Control, Positive Control, Cytometry, Control

    Figure 6. The scratch assay (cell migration) was performed for PRI-724, vismodegib, erlotinib, HS- 173, and their combinations in CAL 27 (A–C) and FaDu (D–F) cells. Results (mean values ± SD) were calculated from four experiments (A,D). The asterisk (*) above the bars denotes a statistically significant decrease in migration rate between the analyzed compound used alone or in combination, and the control (ctrl), * p < 0.05, ** p < 0.01, *** p < 0.001. Exemplary microscopic images of the scratch, which were taken at the beginning and after 18 h of incubation with the compounds, are shown (B,E). The scale bar represents 500 µm. The assessment of the type of interaction between compounds using the modified Bürgi formula is shown (C,F). The addition of effects (0.85 ≤q ≤1.15) is highlighted in yellow, while synergistic effects (q > 1.15) are highlighted in green.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 6. The scratch assay (cell migration) was performed for PRI-724, vismodegib, erlotinib, HS- 173, and their combinations in CAL 27 (A–C) and FaDu (D–F) cells. Results (mean values ± SD) were calculated from four experiments (A,D). The asterisk (*) above the bars denotes a statistically significant decrease in migration rate between the analyzed compound used alone or in combination, and the control (ctrl), * p < 0.05, ** p < 0.01, *** p < 0.001. Exemplary microscopic images of the scratch, which were taken at the beginning and after 18 h of incubation with the compounds, are shown (B,E). The scale bar represents 500 µm. The assessment of the type of interaction between compounds using the modified Bürgi formula is shown (C,F). The addition of effects (0.85 ≤q ≤1.15) is highlighted in yellow, while synergistic effects (q > 1.15) are highlighted in green.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Wound Healing Assay, Migration, Control, Incubation

    Figure 8. The effect of PRI-724 and vismodegib on the relative transcript levels of ALDH1A1, SOX2, and POU5F1 genes in CAL 27 (A) and FaDu (B) cells. Mean values ± SD from three independent experiments with three replicates per R-T PCR reaction are shown. The level of DMSO-treated cells was considered to be 1. The asterisk (*) above the bar denotes statistically significant changes in comparison to control (* p < 0.05, ** p < 0.01), (#) denotes statistically significant changes in comparison to PRI-724 (# p < 0.05, ## p < 0.01), and (ˆ) denotes statistically significant changes in comparison to vismodegib (ˆˆ p < 0.01).

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 8. The effect of PRI-724 and vismodegib on the relative transcript levels of ALDH1A1, SOX2, and POU5F1 genes in CAL 27 (A) and FaDu (B) cells. Mean values ± SD from three independent experiments with three replicates per R-T PCR reaction are shown. The level of DMSO-treated cells was considered to be 1. The asterisk (*) above the bar denotes statistically significant changes in comparison to control (* p < 0.05, ** p < 0.01), (#) denotes statistically significant changes in comparison to PRI-724 (# p < 0.05, ## p < 0.01), and (ˆ) denotes statistically significant changes in comparison to vismodegib (ˆˆ p < 0.01).

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Comparison, Control

    Figure 9. A summary of the main concepts and results of the study. Wnt/β-catenin signaling was inhibited by the PRI-724 small molecule, which targets the interaction between nuclear β-catenin and the CREB binding protein (CBP). PRI-724 was combined with the Hedgehog pathway inhibitor vismodegib, which blocks the Smoothened protein; the epidermal growth factor receptor (EGFR) pathway inhibitor erlotinib, which interacts with the cytoplasmic tyrosine kinase domains of EGFR; and the phosphoinositide 3-kinase (PI3K) inhibitor HS-173, which targets the p110α domain of PI3K. The effects detected in CAL 27 and FaDu cells after treatment with each combination of inhibitors used in this research are listed in the frame (upper panel), and appropriate numbers appear next to arrows denoting compound mixes in the head and neck cancer cell schematic representation. CSC, cancer stem cells; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate.

    Journal: International journal of molecular sciences

    Article Title: Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

    doi: 10.3390/ijms241310448

    Figure Lengend Snippet: Figure 9. A summary of the main concepts and results of the study. Wnt/β-catenin signaling was inhibited by the PRI-724 small molecule, which targets the interaction between nuclear β-catenin and the CREB binding protein (CBP). PRI-724 was combined with the Hedgehog pathway inhibitor vismodegib, which blocks the Smoothened protein; the epidermal growth factor receptor (EGFR) pathway inhibitor erlotinib, which interacts with the cytoplasmic tyrosine kinase domains of EGFR; and the phosphoinositide 3-kinase (PI3K) inhibitor HS-173, which targets the p110α domain of PI3K. The effects detected in CAL 27 and FaDu cells after treatment with each combination of inhibitors used in this research are listed in the frame (upper panel), and appropriate numbers appear next to arrows denoting compound mixes in the head and neck cancer cell schematic representation. CSC, cancer stem cells; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate.

    Article Snippet: The Wnt canonical signaling inhibitor PRI-724, the Hedgehog signaling inhibitor vismodegib, and the EGF receptor intracellular domain inhibitor erlotinib were ordered from Selleck Chemicals (Pittsburgh, PA, USA), while the inhibitor of the p110α domain of PI3K was purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Techniques: Binding Assay